No Data
Express News | Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $45 Price Target
Bristol-Myers Squibb Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 5.07% Cantor Fitzgerald $45 → $45 Reiterates Neutral → Neutral 07/10/2024 -4.27% Barclays $43 →
Express News | Bristol-Myers Squibb Co : Jefferies Cuts Target Price to $49 From $54
Trump Media, CrowdStrike, Tesla, Verizon, Ryanair, and More Stock Market Movers
Trump Media stock rises after President Biden ends his run for reelection, CrowdStrike extends losses after the global IT outage on Friday, Verizon reports earnings Monday, and Tesla issues its profit report on Tuesday.
Kamala Harris' Potential Impact on Health Care Stocks
With President Joe Biden earlier Sunday saying he will end his campaign for re-election and endorsing Vice President Kamala Harris, the focus now turns on her positions on issues.
Investors in Bristol-Myers Squibb (NYSE:BMY) From Three Years Ago Are Still Down 30%, Even After 5.4% Gain This Past Week
10baggerbamm : big day Wednesday hopefully we see I knock the cover off the ball moment exceed whisper number exceed revenue number and exceed forward guidance expectations if we can achieve that it's over 100 bucks